The prognostic value of the plasma N-terminal pro-brain natriuretic peptide level on all-cause death and major cardiovascular events in a community-based population

Clinical Interventions in Aging

Volumn 11, Issue , 2016, Pages 245-253

  Zhu, Qiwei ^a   Xiao, Wenkai ^a   Bai, Yongyi ^a   Ye, Ping ^a   Luo, Leiming ^a   Gao, Peng ^a   Wu, Hongmei ^a   Bai, Jie ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Community population; NT proBNP; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; GLUCOSE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GLUCOSE BLOOD LEVEL; LIPID; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMMUNITY SAMPLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; ANALYSIS; BLOOD; CHINA; CHRONIC KIDNEY FAILURE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BEIJING; BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CREATININE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LIPIDS; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SURVEYS AND QUESTIONNAIRES;

EID: 84959461260     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S98151     Document Type: Article

References (28)

1. Santaguida PL, Don-Wauchope AC, Oremus M, et al. BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Fail Rev. 2014;19(4): 453–470.
2. Don-Wauchope AC, McKelvie RS. Evidence based application of BNP/NT-proBNP testing in heart failure. Clin Biochem. 2015; 48(4–5):236–246.
3. Kara K, Lehmann N, Neumann T, et al. NT-proBNP is superior to BNP for predicting first cardiovascular events in the general population: the Heinz Nixdorf Recall Study. Int J Cardiol. 2015;183:155–161.
4. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–167.
5. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352(7):666–675.
6. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350(7):655–663.
7. Laukkanen JA, Kurl S, la-Kopsala M, et al. Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men. Eur Heart J. 2006;27(10): 1230–1237.
8. Linssen GC, Bakker SJ, Voors AA, et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J. 2010;31(1):120–127.
9. Shankar A, Leng C, Chia KS, et al. Association between body mass index and chronic kidney disease in men and women: population based study of Malay adults in Singapore. Nephrol Dial Transplant. 2008;23(6):1910–1918.
10. Hu J, Wallace DC, Jones E, Liu H. Cardiometabolic health of Chinese older adults with diabetes living in Beijing, China. Public Health Nurs. 2009;26(6):500–511.
11. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937–2944.
12. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KIDGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1): 1–150.
13. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–1252.
14. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631–2639.
15. Sarimehmetoglu AC, Gultekin N, Kucukates E, Yildiz A, Kocas C, Ersanli M. The importance of apoptotic activity and plasma NT-proBNP levels in patients with acute exacerbation of decompensated heart failure and their relation to different drugs and comorbidities. J Pak Med Assoc. 2014;64(8):884–891.
16. Oremus M, Don-Wauchope A, McKelvie R, et al. BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail Rev. 2014;19(4):471–505.
17. Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation. 2004;109(23):2872–2877.
18. Harada M, Saito Y, Kuwahara K, et al. Interaction of myocytes and nonmyocytes is necessary for mechanical stretch to induce ANP/BNP production in cardiocyte culture. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S357–S359.
19. Sargento L, Longo S, Lousada N, Palma Dos Reis R. Serial measurements of the Nt-ProBNP during the dry state in patients with systolic heart failure are predictors of the long-term prognosis. Biomarkers. 2014;19(4):302–313.
20. Beleigoli AM, Ribeiro AL, Diniz Mde F, Lima-Costa MF, Boersma E. Comparing the value of BNP in predicting mortality among community-dwelling elderly with and without overweight/obesity: the Bambuí (Brazil) Cohort Study of Aging. Int J Cardiol. 2013;168(4):4364–4366.
21. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005;293(13):1609–1616.
22. Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E. Minimally elevated cardiac troponinT and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol. 2008;52(6):450–459.
23. Van Peet PG, de Craen AJ, Gussekloo J, de Ruijter W. Plasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old: the Leiden 85-plus study. Age. 2014;36(3):1541–1554.
24. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813–1821.
25. Zhu M, Li J, Li Z, et al. Mortality rates and the causes of death related to diabetes mellitus in Shanghai Songjiang District: an 11-year retrospective analysis of death certificates. BMC Endocr Disord. 2015; 15(1):45.
26. Di Angelantonio E, Chowdhury R, Sarwar N, et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation. 2009;120(22):2177–2187.
27. Fuat A, Murphy JJ, Hungin AP, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract. 2006;56(526):327–333.
28. Taylor CJ, Roalfe AK, Iles R, Hobbs FD. The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis. BMJ Open. 2014;4(4):e004675.